Symptom evaluation in gastroesophageal reflux disease

Journal of Clinical Gastroenterology

Volumn 42, Issue 5, 2008, Pages 558-563

  Modlin, Irvin M ^a,c   Moss, Steven F ^b  

^a YALE UNIVERSITY   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acid; Evaluation; GERD; NERD; PPI; ReQuest

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; PANTOPRAZOLE; PROTON PUMP INHIBITOR;

CONFERENCE PAPER; ENDOSCOPY; ESOPHAGUS INJURY; ESOPHAGUS MUCOSA; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; INTESTINE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SLEEP DISORDER; SYMPTOM;

DISEASE PROGRESSION; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL MOTILITY; HUMANS; PROGNOSIS; PROTON PUMP INHIBITORS;

EID: 42449162386     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e31816207cb     Document Type: Conference Paper

References (39)

1. Moayyedi P, Talley NJ. Gastro-oesophageal reflux disease. Lancet. 2006;367:2086-2100.
2. Shaheen NJ, Hansen RA, Morgan DR, et al. The burden of gastrointestinal and liver diseases, 2006. Am J Gastroenterol. 2006; 101:2128-2138.
3. Dimenas E, Glise H, Hallerback B, et al. Quality of life in patients with upper gastrointestinal symptoms. An improved evaluation of treatment regimens? Scand J Gastroenterol. 1993;28:681-687.
4. Modlin IM, Kidd M, Lye KD. Historical perspectives on the treatment of gastroesophageal reflux disease. Gastrointest Endosc Clin N Am. 2003;13:19-55.
5. Galmiche JP, Bruley des Varannes S. Symptoms and disease severity in gastro-oesophageal reflux disease. Scand J Gastroenterol Suppl. 1994;201:62-68.
6. Chiba N, De Gara CJ, Wilkinson JM, et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology. 1997;112:1798-1810.
7. El-Serag HB, Lau M. Temporal trends in new and recurrent oesophageal strictures in a Medicare population. Aliment Pharmacol Ther. 2007;25:1223-1229.
8. Bardhan KD, Achim A, Riddermann T, et al. A clinical trial comparing pantoprazole and esomeprazole to explore the concept of achieving "complete remission" in gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2007;25:1461-1469.
9. Locke GR, Zinsmeister AR, Talley NJ. Can symptoms predict endoscopic findings in GERD? Gastrointest Endosc. 2003;58:661-670.
10. Labenz J, Jaspersen D, Kulig M, et al. Risk factors for erosive esophagitis: a multivariate analysis based on the ProGERD study initiative. Am J Gastroenterol. 2004;99:1652-1656.
11. Sharma P, Wani S, Bansal A, et al. A feasibility trial of narrow band imaging endoscopy in patients with gastroesophageal reflux disease. Gastroenterology. 2007;133:454-464.
12. Calabrese C, Fabbri A, Bortolotti M, et al. Dilated intercellular spaces as a marker of oesophageal damage: comparative results in gastro-oesophageal reflux disease with or without bile reflux. Aliment Pharmacol Ther. 2003;18:525-532.
13. Caviglia R, Ribolsi M, Gentile M, et al. Dilated intercellular spaces and acid reflux at the distal and proximal oesophagus in patients with non-erosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2007;25:629-636.
14. Kiesslich R, Kanzler S, Vieth M, et al. Minimal change esophagitis: prospective comparison of endoscopic and histological markers between patients with non-erosive reflux disease and normal controls using magnifying endoscopy. Dig Dis. 2004;22:221-227.
15. Labenz J, Nocon M, Lind T, et al. Prospective follow-up data from the ProGERD study suggest that GERD is not a categorical disease. Am J Gastroenterol. 2006;101:2457-2462.
16. Quigley EM. Functional dyspepsia (FD) and non-erosive reflux disease (NERD): overlapping or discrete entities? Best Pract Res Clin Gastroenterol. 2004;18:695-706.
17. Shaker R, Castell DO, Schoenfeld PS, et al. Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association. Am J Gastroenterol. 2003;98:1487-1493.
18. Bardhan KD, Stanghellini V, Armstrong D, et al. Evaluation of GERD symptoms during therapy. Part I. Development of the new GERD questionnaire ReQuest. Digestion. 2004;69:229-237.
19. Monnikes H. Global clinical symptom spectrum in gastroesophageal reflux disease. J Clin Gastroenterol. 1997;41(suppl 2):S168-S174.
20. Dent DJ, Brun J, Fendrick AM, et al. An evidence-based appraisal of reflux disease management the Genval Workshop Report. Gut. 1998;44(suppl 2):S1-S16.
21. Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101:1900-1920.
22. Stanghellini V, Armstrong D, Monnikes H, et al. Systematic review: do we need a new gastro-oesophageal reflux disease questionnaire? Aliment Pharmacol Ther. 2004;19:463-479.
23. Fraser A, Delaney B, Moayyedi P. Symptom-based outcome measures for dyspepsia and GERD trials: a systematic review. Am J Gastroenterol. 2005;100:442-452.
24. Fass R. Symptom assessment tools for gastroesophageal reflux disease (GERD) treatment. J Clin Gastroenterol. 2007;41:437-444.
25. Armstrong D, Monnikes H, Bardhan KD, et al. The construction of a new evaluative GERD questionnaire-methods and state of the art. Digestion. 2004;70:71-78.
26. Bardhan KD, Stanghellini V, Armstrong D, et al. International validation of ReQuest in patients with endoscopy-negative gastrooesophageal reflux disease. Aliment Pharmacol Ther. 2004;20:891-898.
27. Monnikes H, Bardhan KD, Stanghellini V, et al. Evaluation of GERD symptoms during therapy. Part II. Psychometric evaluation and validation of the new questionnaire ReQuest in erosive GERD. Digestion. 2004;69:238-244.
28. Bardhan KD, Berghofer P. Look-but also listen! ReQuest: an essay on a new validated scale to assess the outcome of GERD treatment. Digestion. 2007;75(suppl 1):87-100.
29. Heading RC, Bardhan KD, Sander P, et al. Application of the complete remission concept: many patients with GERD are incompletely treated by a standard proton pump inhibitor regime (abstract). Gut. 2006;55(suppl V):A62.
30. Achim A, Riddermann T, Bethke TD, et al. A new integrated approach for assessing the effectiveness of pantoprazole and esomeparazole treatment in patients with gastroesophageal reflux disease. Gastroenterology. 2005;128(suppl 2):A528.
31. Venables TL, Newland RD, Patel AC, et al. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol. 1997;32:965-973.
32. Carlsson R, Dent J, Watts R, et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol. 1998;10:119-124.
33. Dean BB, Gano AD Jr, Knight K, et al. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol. 2004;2:656-664.
34. Monnikes H, Pfaffenberger B, Gatz G, et al. Novel measurement of rapid treatment success with ReQuest: first and sustained symptom relief as outcome parameters in patients with endoscopy-negative GERD receiving 20mg pantoprazole or 20 mg esomeprazole. Digestion. 2005;71:152-158.
35. Glatzel D, Abdel-Qader M, Gatz G, et al. Pantoprazole 40 mg is as effective as esomeprazole 40 mg to relieve symptoms of gastroesophageal reflux disease after 4 weeks of treatment and superior regarding the prevention of symptomatic relapse. Digestion. 2007;75(suppl 1):69-78.
36. Bardhan KD. Look-but also listen! ReQuest: a new dimensionoriented GERD symptom scale. Drugs Today (Barc). 2004;40(suppl A):15-19.
37. Fass R, Bothe G, Heinze H, et al. Pantoprazole improves symptoms of gastroesophageal reflux disease beyond heartburn (abstract). United European Gastroenterology Week. 2007.
38. Bardhan KD, Heading RC, Sander P. Differences in the assessment of gastrointestinal symptoms by investigator versus patients themselves (abstract). United European Gastroenterology Week. 2007.
39. Holtmann G, Hunt R, Katelaris P, et al. What is the truth? Sleep disturbance as assessed by investigators or a validated instrument (Requestt) in patients with gastro-esophageal reflux disease (GERD) (abstract). Am J Gastroenterol. 2007;103(suppl 2):S124.